Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 14;16(1):101.
doi: 10.1186/s12939-017-0601-3.

Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study

Affiliations

Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study

Kyriakos Souliotis et al. Int J Equity Health. .

Abstract

Background: Evidence suggests that Greece is among the European countries with increased trend in HCV prevalence among injecting drug users (IDUs) from 2008 to 2014. Nonetheless, the access of IDUs to treatment for Hepatitis C Virus (HCV) is very limited while the risk of co-infection and transmission remains high. In an effort to better understand the inhibitors to HCV treatment, the present study aimed to investigate the main barriers to access in a sample of IDUs.

Methods: The cross-sectional study was carried out between July and September 2015 using a 23-items questionnaire. Participants were recruited from urban primary services, mobile health vans, community health services, day-care centers as well as during street work, located in Athens, Greece. Inclusion criteria were age above 18 years, understanding and speaking Greek sufficiently, HCV diagnosis, intravenous drug use. Data collection was carried out by health professionals of Praksis, a non-governmental organization. For the comparisons of proportions chi-square and Fisher's exact tests were used.

Results: The study sample consisted of 101 HCV patients, 68% male. More than 80% of study participants experienced barriers in accessing their doctor and medication during the past 12 months. The most common obstacles in accessing a doctor were "delay in making the appointment and "difficulties in going to the doctor due to health condition or lack of means of transport". Access to physician or medication was not differed according to gender, but significant differences were found according to economic status and health insurance coverage. 56.1% of participants reported loss or treatment delay due to barriers to treatment. The majority of participants had deteriorated financial status, health status, access to health services and medication, higher financial burden for health services, worse mental health and lower adherence to medical instructions in 2015 compared to 2009.

Conclusions: The findings from the present study revealed that the vast majority of IDUs experience significant barriers in seeking HCV care in Greece, thus highlighting the need for immediate action in this particular area due to the high risk of co-infection and transmission.

Keywords: Barriers; Economic crisis; Greece; HCV; Healthcare; Hepatitis C; Injecting drug users; Patient access; Pharmaceuticals; Recession.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Consequences of barriers to access to HCV treatment
Fig. 2
Fig. 2
Assessment of current economical and health issues in comparison with 2009

Similar articles

Cited by

References

    1. Nyamathi A, Salem BE, Marlow E, Zhang S, Yadav K. Understanding correlates of hepatitis C virus infection among homeless recently paroled men. J Forensic Nurs. 2013;9:161–70. doi: 10.1097/JFN.0b013e31827a5908. - DOI - PMC - PubMed
    1. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. doi: 10.1186/1471-2334-13-181. - DOI - PMC - PubMed
    1. EMCDDA . Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2016.
    1. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33:126–33. doi: 10.1007/s10900-007-9083-3. - DOI - PMC - PubMed
    1. Mathei C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat. 2002;9:157–73. doi: 10.1046/j.1365-2893.2002.00339.x. - DOI - PubMed
-